REVIEW
Osteopathic manipulative treatment for chronic inflammatory diseases
Ross Gillan,
Gabrielle Bachtel,
Kassidy Webber,
Yasmine Ezzair,
Nicole E. Myers,
Anupam Bishayee,
Ross Gillan
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
Search for more papers by this authorGabrielle Bachtel
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
Search for more papers by this authorKassidy Webber
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
Search for more papers by this authorYasmine Ezzair
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
Search for more papers by this authorNicole E. Myers
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
Search for more papers by this authorCorresponding Author
Anupam Bishayee
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
Correspondence
Anupam Bishayee, College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, 5000 Lakewood Ranch Boulevard, Bradenton, FL 34211, USA.
Email: abishayee@lecom.edu; abishayee@gmail.com
Search for more papers by this authorRoss Gillan,
Gabrielle Bachtel,
Kassidy Webber,
Yasmine Ezzair,
Nicole E. Myers,
Anupam Bishayee,
Ross Gillan
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
Search for more papers by this authorGabrielle Bachtel
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
Search for more papers by this authorKassidy Webber
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
Search for more papers by this authorYasmine Ezzair
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
Search for more papers by this authorNicole E. Myers
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
Search for more papers by this authorCorresponding Author
Anupam Bishayee
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
Correspondence
Anupam Bishayee, College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, 5000 Lakewood Ranch Boulevard, Bradenton, FL 34211, USA.
Email: abishayee@lecom.edu; abishayee@gmail.com
Search for more papers by this authorFirst published: 15 March 2024
Ross Gillan, Gabrielle Bachtel, and Kassidy Webber contributed equally to this work.
Abstract
Chronic inflammatory diseases (CIDs) are debilitating and potentially lethal illnesses that affect a large proportion of the global population. Osteopathic manipulative treatment (OMT) is a manual therapy technique developed and performed by osteopathic physicians that facilitates the body's innate healing processes. Therefore, OMT may prove a beneficial anti-inflammatory modality useful in the management and treatment of CIDs. This work aims to objectively evaluate the therapeutic benefits of OMT in patients with various CIDs. In this review, a structured literature search was performed. The included studies involving asthma, chronic obstructive pulmonary disease, irritable bowel syndrome, ankylosing spondylitis, and peripheral arterial disease were selected for this work. Various OMT modalities, including lymphatic, still, counterstain, and muscle energy techniques, were utilized. Control treatments included sham techniques, routine care, or no treatment. OMT utilization led to variable patient outcomes in individuals with pathologies linked to CID.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflicts of interest.
REFERENCES
- 1Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Elsevier; 2020.
- 2Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019; 25(12): 1822-1832.
- 3Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020; 180:114147.
- 4Prashar R, Venkat KK. Immunosuppression minimization and avoidance protocols: when less is not more. Adv Chronic Kidney Dis. 2016; 23(5): 295-300.
- 5Gurnell M, Heaney LG, Price D, et al. Long-term corticosteroid use, adrenal insufficiency and the need for steroid-sparing treatment in adult severe asthma. J Intern Med. 2021; 290(2): 240-256.
- 6 Task Force on the Low Back Pain Clinical Practice Guidelines. American Osteopathic Association guidelines for Osteopathic Manipulative Treatment (OMT) for patients with low back pain. J Am Osteopath Assoc. 2016; 116(8): 536-549.
- 7Müller A, Franke H, Resch KL, et al. Effectiveness of osteopathic manipulative therapy for managing symptoms of irritable bowel syndrome: a systematic review. J Am Osteopath Assoc. 2014; 114(6): 470-479.
- 8Cicchitti L, Martelli M, Cerritelli F. Chronic inflammatory disease and osteopathy: a systematic review. PLoS One. 2015; 10(3):e0121327.
- 9Licciardone JC, Kearns CM, Hodge LM, et al. Osteopathic manual treatment in patients with diabetes mellitus and comorbid chronic low back pain: subgroup results from the OSTEOPATHIC Trial. J Am Osteopath Assoc. 2013a; 113(6): 468-478.
- 10Castillo R, Schander A, Hodge LM. Lymphatic pump treatment mobilizes bioactive lymph that suppresses macrophage activity in vitro. J Am Osteopath Assoc. 2018; 118(7): 455-461.
- 11Ruffini N, D'Alessandro G, Mariani N, et al. Variations of high frequency parameter of heart rate variability following osteopathic manipulative treatment in healthy subjects compared to control group and sham therapy: randomized controlled trial. Front Neurosci. 2015; 9: 272.
- 12Bonaz B, Sinniger V, Pellissier S. Therapeutic potential of vagus nerve stimulation for inflammatory bowel diseases. Front Neurosci. 2021; 15:650971.
- 13Collebrusco L, Lombardini R. What about OMT and nutrition for managing the irritable bowel syndrome? An overview and treatment plan. Explore. 2014; 10(5): 309-318.
- 14Zein-Hammoud M, Standley PR. Modeled osteopathic manipulative treatments: a review of their in vitro effects on fibroblast tissue preparations. J Am Osteopath Assoc. 2015; 115(8): 490-502.
- 15Parravicini G, Bergna A. Biological effects of direct and indirect manipulation of the fascial system. Narrative review. J Bodyw Mov Ther. 2017; 21(2): 435-445.
- 16Leicht BT, Kennedy C, Richardson C. Inflammatory biochemical mediators and their role in myofascial pain and osteopathic manipulative treatment: a literature review. Cureus. 2022; 14(2):e22252.
- 17Marin T, Maxel X, Robin A, et al. Evidence-based assessment of potential therapeutic effects of adjunct osteopathic medicine for multidisciplinary care of acute and convalescent COVID-19 patients. Explore. 2021; 17(2): 141-147.
- 18Licciardone JC, Kearns CM, Minotti DE. Outcomes of osteopathic manual treatment for chronic low back pain according to baseline pain severity: results from the OSTEOPATHIC trial. Man Ther. 2013b; 18(6): 533-540.
- 19Meltzer KR, Cao TV, Schad JF, et al. In vitro modeling of repetitive motion injury and myofascial release. J Bodyw Mov Ther. 2010; 14(2): 162-171.
- 20Pahwa R, Goyal A, Jialal I. Chronic inflammation. In: Chronic Inflammation. StatPearls - NCBI bookshelf; 2022. . [Accessed December 30, 2022]. https://www.ncbi.nlm.nih.gov/books/NBK493173/
- 21Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet North Am Ed. 2012; 380(9836): 37-43.
- 22Wu H, Mach J, Gnjidic D, et al. Comparing effects of polypharmacy on inflammatory profiles in older adults and mice: implications for translational aging research. J Gerontol A Biol Sci Med Sci. 2022; 77(7): 1295-1303.
- 23Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy. JAMA Intern Med. 2015; 175(5): 827.
- 24Morgan ET. Regulation of drug-metabolizing enzymes and drug metabolism by inflammatory responses. In: Drug Metabolism in Diseases. Academic Press; 2017: 21-58.
10.1016/B978-0-12-802949-7.00002-X Google Scholar
- 25Wu KC, Lin CJ. The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: evidences in inflammatory diseases and age-related disorders. J Food Drug Anal. 2019; 27(1): 48-59.
- 26Stanke-Labesque F, Gautier-Veyret E, Chhun S, et al. Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther. 2020; 215:107627.
- 27Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 2014; 43(3): 400-410.
- 28Garin N, Sole N, Lucas B, et al. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci Rep. 2021; 11(1): 883.
- 29Almodóvar AS, Nahata MC. Associations between chronic disease, polypharmacy, and medication-related problems among medicare beneficiaries. J Manag Care Spec Pharm. 2019; 25(5): 573-577.
- 30Nicosia FM, Spar MJ, Stebbins M, et al. What is a medication-related problem? A qualitative study of older adults and primary care clinicians. J Gen Intern Med. 2019; 35(3): 724-731.
- 31Maniadakis N, Toth E, Schiff M, et al. A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences. Adv Ther. 2018; 35(9): 1333-1355.
- 32Lee JS, Yang J, Stockl KM, et al. Evaluation of eligibility criteria used to identify patients for medication therapy management services: a retrospective cohort study in a Medicare advantage part D population. J Manag Care Spec Pharm. 2016; 22(1): 22-30.
- 33Singh S, Qian AS, Nguyen NH, et al. Trends in U.S. health care spending on inflammatory bowel diseases, 1996–2016. Inflamm Bowel Dis. 2021; 28(3): 364-372.
- 34Scully RE, Arnaoutakis DJ, DeBord Smith A, et al. Estimated annual health care expenditures in individuals with peripheral arterial disease. J Vasc Surg. 2018; 67(2): 558-567.
- 35Nurmagambetov T, Kuwahara R, Garbe P. The economic burden of asthma in the United States, 2008–2013. Ann Am Thorac Soc. 2018; 15(3): 348-356.
- 36Wallace AE, Kaila S, Bayer V, et al. Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. J Manag Care Spec Pharm. 2019; 25(2): 205-217.
- 37Castells M. Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations. Front Immunol. 2017; 8: 1472.
- 38Van Wilder L, Devleesschauwer B, Clays E, et al. Polypharmacy and health-related quality of life/psychological distress among patients with chronic disease. Prev Chronic Dis. 2022; 19:220062.
- 39Osanlou R, Walker L, Hughes DA, et al. Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of Medical Admissions. BMJ Open. 2022; 12(7):e055551.
- 40Hakkarainen KM, Hedna K, Petzold M, et al. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions—a meta-analysis. PLoS One. 2012; 7(3):e33236.
- 41Ismail H, Marshall VD, Patel M, et al. The impact of the COVID-19 pandemic on medical conditions and medication adherence in people with chronic diseases. J Am Pharm Assoc (Wash DC). 2022; 62(3): 834-839 e1.
- 42Friedman E, Shorey C. Inflammation in multimorbidity and disability: an integrative review. Health Psychol. 2019; 38(9): 791-801.
- 43Muscatell KA, Brosso SN, Humphreys KL. Socioeconomic status and inflammation: a meta-analysis. Mol Psychiatry. 2018; 25(9): 2189-2199.
- 44Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009; 62(10): e1-e34.
- 45Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Brit Med J. 2021; 372: n71.
- 46Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016; 138(1): 16-27.
- 47Noll DR, Degenhardt BF, Johnson JC, et al. Immediate effects of osteopathic manipulative treatment in elderly patients with chronic obstructive pulmonary disease. J Am Osteopath Assoc. 2008; 108(5): 251-259.
- 48Zanotti E, Berardinelli P, Bizzarri C, et al. Osteopathic manipulative treatment effectiveness in severe chronic obstructive pulmonary disease: a pilot study. Complement Ther Med. 2012; 20(1-2): 16-22. doi:10.1016/j.ctim.2011.10.008
- 49Bhilpawar PP, Arora R. Effects of osteopathic manipulative treatment in patients with chronic obstructive pulmonary disease. Indian J Physiother Occup Ther. 2013; 7(1): 196-201.
- 50Baxter DA, Coyle ME, Hill CJ, et al. Muscle energy technique for chronic obstructive pulmonary disease: a feasibility study. J Integr Med. 2023; 21(3): 245-253.
- 51Bockenhauer SE, Julliard KN, Lo KS, et al. Quantifiable effects of osteopathic manipulative techniques on patients with chronic asthma. J Am Osteopath Assoc. 2002; 102(7): 371-375.
- 52Guiney PA, Chou R, Vianna A, et al. Effects of osteopathic manipulative treatment on pediatric patients with asthma: a randomized controlled trial. J Am Osteopath Assoc. 2005; 105(1): 7-12.
- 53Jones LM, Regan C, Wolf K, et al. Effect of osteopathic manipulative treatment on pulmonary function testing in children with asthma. J Osteopath Med. 2021; 121(6): 589-596.
- 54Murphy A. Knowing the differences between COPD and asthma is vital to good practice. Pharm J. 2011. doi:10.1211/PJ.2021.1.72725 https://pharmaceutical-journal.com/article/ld/knowing-the-differences-between-copd-and-asthma-is-vital-to-good-practice
10.1211/PJ.2021.1.72725 Google Scholar
- 55Attali TV, Bouchoucha M, Benamouzig R. Treatment of refractory irritable bowel syndrome with visceral osteopathy: short-term and long-term results of a randomized trial. J Dig Dis. 2013; 14(12): 654-661.
- 56Florance BM, Frin G, Dainese R, et al. Osteopathy improves the severity of irritable bowel syndrome: a pilot randomized sham-controlled study. Eur J Gastroenterol Hepatol. 2012; 24(8): 944-949.
- 57Golder V, Schachna L. Ankylosing spondylitis: an update. Aust Fam Physician. 2013; 42(11): 780-784.
- 58Seiler M, Vermeylen B, Poortmans B, et al. Effects of non-manipulative osteopathic management in addition to physical therapy and rehabilitation on clinical outcomes of ankylosing spondylitis patients: a preliminary randomized clinical trial. J Bodyw Mov Ther. 2020; 24(4): 51-56.
- 59Brevetti G, Giugliano G, Brevetti L, et al. Inflammation in peripheral artery disease. Circulation. 2010; 122(18): 1862-1875.
- 60Lombardini R, Marchesi S, Collebrusco L, et al. The use of osteopathic manipulative treatment as adjuvant therapy in patients with peripheral arterial disease. Man Ther. 2009; 14(4): 439-443.
- 61Bordoni B. The benefits and limitations of evidence-based practice in osteopathy. Cureus. 2019; 11(11):e6093.
- 62Sundberg T, Leach MJ, Thomson OP, et al. Attitudes, skills and use of evidence-based practice among UK osteopaths: a national cross-sectional survey. BMC Musculoskelet Disord. 2018; 19(1): 439.
- 63Leach MJ, Sundberg T, Fryer G, et al. An investigation of Australian osteopaths’ attitudes, skills and utilisation of evidence-based practice: a national cross-sectional survey. BMC Health Serv Res. 2019; 19(1): 498.
- 64Cerritelli F, Iacopini A, Galli M, et al. Evidence-based practice among Italian osteopaths: a national cross-sectional survey. BMC Complement Med Ther. 2021; 21(1): 252.
- 65Morin C, Gaboury I. Osteopathic empirical research: a bibliometric analysis from 1966 to 2018. BMC Complement Med Ther. 2021; 21(1): 196.
- 66 FDA-NIH BioMarker Working Group. Best (Biomarkers, Endpoints, and Other Tools) Resource. NCBI bookshelf; 2020. [Accessed December 30, 2022]. https://www.ncbi.nlm.nih.gov/books/NBK326791/
- 67Ou FS, Michiels S, Shyr Y, et al. Biomarker discovery and validation: statistical considerations. J Thorac Oncol. 2021; 16(4): 537-545.
- 68Dodd JG, Good MM, Nguyen TL, et al. In vitro biophysical strain model for understanding mechanisms of osteopathic manipulative treatment. J Am Osteopath Assoc. 2006; 106: 157-166.
- 69McPartland JM. Expression of the endocannabinoid system in fibroblasts and myofascial tissues. J Bodyw Mov Ther. 2008; 12(2): 169-182.
- 70Schander A, Downey HF, Hodge LM. Lymphatic pump manipulation mobilizes inflammatory mediators into lymphatic circulation. Exp Biol Med. 2012; 237(1): 58-63.
- 71Cao TV, Hicks MR, Campbell D, et al. Dosed myofascial release in three-dimensional bioengineered tendons: effects on human fibroblast hyperplasia, hypertrophy, and cytokine secretion. J Manip Physiol Ther. 2013; 36: 513-521.
- 72Anglund DC, Channell MK. Contribution of osteopathic medicine to care of patients with chronic wounds. J Osteopath Med. 2011; 111(9): 538-542.
- 73Yao SC, Hart AD, Terzella MJ. An evidence-based osteopathic approach to parkinson disease. Osteopath Fam Physician. 2013; 5(3): 96-101.
10.1016/j.osfp.2013.01.003 Google Scholar
- 74Barranco-Trabi J, Mank V, Roberts J, et al. Atypical costochondritis: complete resolution of symptoms after rib manipulation and soft tissue mobilization. Cureus. 2021; 13(4):e14369.
- 75Perez LL, Sneed JA, Eland D. Evidence-based osteopathic manipulative treatment for common conditions. Osteopath Fam Physician. 2012; 4(1): 8-12.
10.1016/j.osfp.2011.11.002 Google Scholar
- 76Kania AM, Weiler KN, Kurian AP, et al. Activation of the cholinergic antiinflammatory reflex by occipitoatlantal decompression and transcutaneous auricular vagus nerve stimulation. J Osteopath Med. 2021; 121(4): 401-415.
- 77Schett G, Elewaut D, McInnes IB, et al. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013; 19(7): 822-824.
- 78Barnig C, Bezema T, Calder PC, et al. Activation of resolution pathways to prevent and fight chronic inflammation: lessons from asthma and inflammatory bowel disease. Front Immunol. 2019; 10: 1699.
- 79Fullerton J, Gilroy D. Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov. 2016; 15: 551-567.
- 80Saas P, Vetter M, Maraux M, et al. Resolution therapy: harnessing efferocytic macrophages to trigger the resolution of inflammation. Front Immunol. 2022; 13:1021413.
- 81Schett G, Neurath MF. Resolution of chronic inflammatory disease: universal and tissue-specific concepts. Nat Commun. 2018; 9(1): 3261.
- 82Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018; 128(7): 2657-2669.
- 83Sugimoto MA, Vago JP, Perretti M, et al. Mediators of the resolution of the inflammatory response. Trends Immunol. 2019; 40(3): 212-227.
- 84Perretti M, Dalli J. Resolution pharmacology: focus on pro-resolving annexin A1 and lipid mediators for therapeutic innovation in inflammation. Annu Rev Pharmacol Toxicol. 2023; 63(1): 449-469.
- 85Verzella M, Affede E, Di Pietrantonio L, et al. Tissutal and fluidic aspects in osteopathic manual therapy: a narrative review. Healthcare. 2022; 10(6): 1014.
- 86Bozinovski S, Anthony D, Vlahos R. Targeting pro-resolution pathways to combat chronic inflammation in COPD. J Thorac Dis. 2014; 6(11): 1548-1556.
- 87Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat Rev Immunol. 2015; 16(1): 51-67.
- 88Duvall MG, Bruggemann TR, Levy BD. Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation. Mol Aspects Med. 2017; 58: 44-56.
- 89Barnig C, Frossard N, Levy BD. Towards targeting resolution pathways of airway inflammation in asthma. Pharmacol Ther. 2018; 186: 98-113.
- 90Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol. 2019; 144(1): 1-12.
- 91Stockley RA, Halpin DM, Celli BR, Singh D. Chronic obstructive pulmonary disease biomarkers and their interpretation. Am J Respir Crit Care Med. 2019; 199(10): 1195-1204.
- 92Chiang N, Serhan CN. Specialized pro-resolving mediator network: an update on production and actions. Essays Biochem. 2020; 64(3): 443-462.
- 93Milne S, Sin DD. Biomarkers in chronic obstructive pulmonary disease. Clin Chest Med. 2020; 41(3): 383-394.
- 94Han YH, Lee K, Saha A, et al. Specialized proresolving mediators for therapeutic interventions targeting metabolic and inflammatory disorders. Biomol Ther. 2021; 29(5): 455-464.
- 95Martin-Rodriguez O, Gauthier T, Bonnefoy F, et al. Pro-resolving factors released by macrophages after efferocytosis promote mucosal wound healing in inflammatory bowel disease. Front Immunol. 2021; 12:754475.
- 96Yang A, Wu Y, Yu G, et al. Role of specialized pro-resolving lipid mediators in pulmonary inflammation diseases: mechanisms and development. Respir Res. 2021; 22(1): 204.
- 97Alghoul Z, Yang C, Merlin D. The current status of molecular biomarkers for inflammatory bowel disease. Biomedicines. 2022; 10(7): 1492.
- 98Dalli J, Gomez EA, Jouvene CC. Utility of the specialized pro-resolving mediators as diagnostic and prognostic biomarkers in disease. Biomolecules. 2022; 12(3): 353.
- 99Liu D, Saikam V, Skrada KA, et al. Inflammatory bowel disease biomarkers. Med Res Rev. 2022; 42(5): 1856-1887.
- 100Pantazopoulos I, Magounaki K, Kotsiou O, et al. Incorporating biomarkers in COPD management: the research keeps going. J Pers Med. 2022; 12(3): 379.
- 101Nicholas AS, Nicholas EA. Atlas of osteopathic techniques. 4th ed. Wolters Kluwer Health; 2022.
